FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032435072> ?p ?o ?g. }

• W2032435072 endingPage "370" @default.
• W2032435072 startingPage "363" @default.
• W2032435072 abstract "BACKGROUND: The objective of the current study was to follow up the results of phase 1 testing by evaluating the clinical efficacy of the green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). METHODS: Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 109/L were eligible for this phase 2 trial. Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily. RESULTS: A total of 42 patients received Polyphenon E at a dose of 2000 mg twice daily for up to 6 months. Of these patients, 29 (69%) had Rai stage I to II disease. Patients received a median of 6 cycles of treatment (range, 1 cycle-6 cycles). The most common grade 3 side effects (according to National Cancer Institute Common Terminology Criteria for Adverse Events) were transaminitis (1 patient), abdominal pain (1 patient), and fatigue (1 patient). Clinical activity was observed, with 13 patients (31%) experiencing a sustained reduction of ≥ 20% in the ALC and 20 of 29 patients (69%) with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all lymph node areas. EGCG plasma levels after 1 month of therapy were found to be correlated with reductions in lymphadenopathy (correlation co-efficient, 0.44; P = .02). Overall, 29 patients (69%) fulfilled the criteria for a biologic response with either a sustained decline ≥ 20% in the ALC and/or a reduction ≥ 30% in the sum of the products of all lymph node areas at some point during the 6 months of active treatment. CONCLUSIONS: Daily oral EGCG in the Polyphenon E preparation was well tolerated by patients with CLL in this phase 2 trial. Durable declines in the ALC and/or lymphadenopathy were observed in the majority of patients. Cancer 2013. © 2012 American Cancer Society." @default.
• W2032435072 created "2016-06-24" @default.
• W2032435072 creator A5002515721 @default.
• W2032435072 creator A5022511085 @default.
• W2032435072 creator A5033825180 @default.
• W2032435072 creator A5034349428 @default.
• W2032435072 creator A5041376092 @default.
• W2032435072 creator A5044733637 @default.
• W2032435072 creator A5051752737 @default.
• W2032435072 creator A5054336817 @default.
• W2032435072 creator A5058727428 @default.
• W2032435072 creator A5059451077 @default.
• W2032435072 creator A5065087784 @default.
• W2032435072 creator A5069710184 @default.
• W2032435072 creator A5080387735 @default.
• W2032435072 creator A5086188593 @default.
• W2032435072 creator A5087950597 @default.
• W2032435072 date "2012-07-03" @default.
• W2032435072 modified "2023-10-13" @default.
• W2032435072 title "Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia" @default.
• W2032435072 cites W1501443642 @default.
• W2032435072 cites W1896985636 @default.
• W2032435072 cites W1966517854 @default.
• W2032435072 cites W1975764483 @default.
• W2032435072 cites W1976814214 @default.
• W2032435072 cites W1982822355 @default.
• W2032435072 cites W1983565474 @default.
• W2032435072 cites W1994054846 @default.
• W2032435072 cites W1997116070 @default.
• W2032435072 cites W2000519650 @default.
• W2032435072 cites W2010480099 @default.
• W2032435072 cites W2013738718 @default.
• W2032435072 cites W2049590903 @default.
• W2032435072 cites W2067266295 @default.
• W2032435072 cites W2073632277 @default.
• W2032435072 cites W2076862756 @default.
• W2032435072 cites W2085068039 @default.
• W2032435072 cites W2087027618 @default.
• W2032435072 cites W2093372478 @default.
• W2032435072 cites W2095021992 @default.
• W2032435072 cites W2098741059 @default.
• W2032435072 cites W2103498170 @default.
• W2032435072 cites W2107998933 @default.
• W2032435072 cites W2114459411 @default.
• W2032435072 cites W2124690619 @default.
• W2032435072 cites W2124743242 @default.
• W2032435072 cites W2131700370 @default.
• W2032435072 cites W2136816004 @default.
• W2032435072 cites W2139201942 @default.
• W2032435072 cites W2141680653 @default.
• W2032435072 cites W2166226393 @default.
• W2032435072 cites W2317888977 @default.
• W2032435072 cites W2325739021 @default.
• W2032435072 cites W60865865 @default.
• W2032435072 doi "https://doi.org/10.1002/cncr.27719" @default.
• W2032435072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3902473" @default.
• W2032435072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22760587" @default.
• W2032435072 hasPublicationYear "2012" @default.
• W2032435072 type Work @default.
• W2032435072 sameAs 2032435072 @default.
• W2032435072 citedByCount "144" @default.
• W2032435072 countsByYear W20324350722012 @default.
• W2032435072 countsByYear W20324350722013 @default.
• W2032435072 countsByYear W20324350722014 @default.
• W2032435072 countsByYear W20324350722015 @default.
• W2032435072 countsByYear W20324350722016 @default.
• W2032435072 countsByYear W20324350722017 @default.
• W2032435072 countsByYear W20324350722018 @default.
• W2032435072 countsByYear W20324350722019 @default.
• W2032435072 countsByYear W20324350722020 @default.
• W2032435072 countsByYear W20324350722021 @default.
• W2032435072 countsByYear W20324350722022 @default.
• W2032435072 countsByYear W20324350722023 @default.
• W2032435072 crossrefType "journal-article" @default.
• W2032435072 hasAuthorship W2032435072A5002515721 @default.
• W2032435072 hasAuthorship W2032435072A5022511085 @default.
• W2032435072 hasAuthorship W2032435072A5033825180 @default.
• W2032435072 hasAuthorship W2032435072A5034349428 @default.
• W2032435072 hasAuthorship W2032435072A5041376092 @default.
• W2032435072 hasAuthorship W2032435072A5044733637 @default.
• W2032435072 hasAuthorship W2032435072A5051752737 @default.
• W2032435072 hasAuthorship W2032435072A5054336817 @default.
• W2032435072 hasAuthorship W2032435072A5058727428 @default.
• W2032435072 hasAuthorship W2032435072A5059451077 @default.
• W2032435072 hasAuthorship W2032435072A5065087784 @default.
• W2032435072 hasAuthorship W2032435072A5069710184 @default.
• W2032435072 hasAuthorship W2032435072A5080387735 @default.
• W2032435072 hasAuthorship W2032435072A5086188593 @default.
• W2032435072 hasAuthorship W2032435072A5087950597 @default.
• W2032435072 hasBestOaLocation W20324350722 @default.
• W2032435072 hasConcept C121332964 @default.
• W2032435072 hasConcept C121608353 @default.
• W2032435072 hasConcept C126322002 @default.
• W2032435072 hasConcept C141071460 @default.
• W2032435072 hasConcept C142424586 @default.
• W2032435072 hasConcept C146357865 @default.
• W2032435072 hasConcept C151730666 @default.
• W2032435072 hasConcept C197934379 @default.

• next